Human Angiotensin-Converting Enzyme 2 (ACE2)
£249.00
Prices from £249 (100μg ) – For larger quantities, please contact us.
Product name:
Human Angiotensin-converting enzyme 2 (ACE2)
Product description:
Recombinant Human Angiotensin-converting enzyme 2 (ACE2) soluble form (Q9BYF1|19-615) produced in Nicotiana benthamiana by Agrobacterium-mediated transient expression.
Description
Product name:
Human Angiotensin-converting enzyme 2 (ACE2)
Product description:
Recombinant Human Angiotensin-converting enzyme 2 (ACE2) soluble form (Q9BYF1|19-615) produced in Nicotiana benthamiana by Agrobacterium-mediated transient expression.
Description
Host species: Nicotiana benthamiana
Molecular weight: 71.2 kDa (+ Glycosylation)
Tag: C-terminal 10His-tag
Uses: For in vitro research use only. Not for human in vivo or therapeutic use.
Relevance: Essential counter-regulatory carboxypeptidase of the renin-angiotensin hormone system that is a critical regulator of blood volume, systemic vascular resistance, and thus cardiovascular homeostasis1. Converts angiotensin I to angiotensin 1-9 (anti-hypertrophic)2 and angiotensin II to angiotensin 1-7 (vasodilator and anti-proliferation)3. Acts as a receptor for human coronaviruses SARS-CoV and SARS-CoV-2, as well as human coronavirus NL63/HCoV-NL634.
Specification
Purity: 95 % as shown by SDS-PAGE
Figure 1: reducing 4-20% SDS-PAGE analysis of 5 µg TNFα.
Biological activity: Not tested.
Endotoxin: Not tested.
Storage
Formulation: Lyophilized from 20 mm HEPES pH7.5, 300 mM NaCl, 175 mM Trehalose.
Shipping: Recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.
Stability & Storage: See COA for detailed storage instructions. Lyophilized materials are stable for up to twelve months from date of receipt at -70℃.
It is recommended that reconstituted protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Reconstitution: A hardcopy of COA with reconstitution instructions is included with the product.
Contact us for more information.
References:
1. https://www.uniprot.org/uniprot/Q9BYF1
2. Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, Donovan M, Woolf B, Robison K, Jeyaseelan R, Breitbart RE, Acton S. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res. 2000 Sep 1;87(5):E1-9.
3. Zisman LS, Keller RS, Weaver B, Lin Q, Speth R, Bristow MR, Canver CC. Increased angiotensin-(1-7)-forming activity in failing human heart ventricles: evidence for upregulation of the angiotensin-converting enzyme Homologue ACE2. Circulation. 2003 Oct 7;108(14):1707-12.
4. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, Müller MA, Drosten C, Pöhlmann S. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020 Apr 16;181(2):271-280.e8.
